1. Home
  2. QSI vs ENTX Comparison

QSI vs ENTX Comparison

Compare QSI & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Quantum-Si Incorporated

QSI

Quantum-Si Incorporated

HOLD

Current Price

$0.76

Market Cap

165.6M

Sector

Health Care

ML Signal

HOLD

Logo Entera Bio Ltd.

ENTX

Entera Bio Ltd.

HOLD

Current Price

$2.78

Market Cap

147.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QSI
ENTX
Founded
2013
2010
Country
United States
Israel
Employees
145
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
165.6M
147.4M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
QSI
ENTX
Price
$0.76
$2.78
Analyst Decision
Buy
Strong Buy
Analyst Count
2
1
Target Price
$1.00
$9.00
AVG Volume (30 Days)
2.7M
3.5M
Earning Date
05-07-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.07
Revenue
N/A
$42,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$618.07
N/A
P/E Ratio
N/A
$41.00
Revenue Growth
N/A
N/A
52 Week Low
$0.69
$0.91
52 Week High
$3.10
$4.20

Technical Indicators

Market Signals
Indicator
QSI
ENTX
Relative Strength Index (RSI) 41.79 60.29
Support Level $0.69 $1.26
Resistance Level $1.11 $3.22
Average True Range (ATR) 0.04 0.36
MACD 0.00 0.02
Stochastic Oscillator 45.31 40.43

Price Performance

Historical Comparison
QSI
ENTX

About QSI Quantum-Si Incorporated

Quantum-Si Inc is a life sciences company focused on proteomics research and analytical technologies. It develops single-molecule detection platforms designed to enable next-generation protein sequencing (NGPS) and large-scale protein analysis. Its technology supports massively parallel sequencing of proteins and can also be applied to the study of nucleic acids, providing tools for researchers and clinical applications in molecular analysis. The company's revenue is derived from sales of products and services.

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.

Share on Social Networks: